Other targeted strategies also failed: the ARISER trial of girentuximab (anti-CAIX antibody) in 864 patients showed no difference in DFS (HR 0.97) or OS (HR 0.99), with only a small exploratory signal in the tumor with very high CAIX expression [42]. This evidence concerns the gene CA9 and neoplasm.